Tolvaptan for Heart Failure, Systematic Review and Meta-Analysis of Trials
E Alskaf1, A Tridente, A Al-Mohammad
1*Cardiology Department, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom; †ICU, Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS Trust, Liverpool, United Kingdom; and ‡Heart Failure Services, Cardiology Department, Northern General Hospital, Sheffield Teaching, Hospitals, Sheffield, United Kingdom.
Journal of Cardiovascular Pharmacology
|May 10, 2016
Summary
Tolvaptan (TLV) offers short-term benefits for heart failure patients by reducing weight and increasing urine and sodium levels. Its long-term impact on mortality remains uncertain, though it appears safe for renal function and blood pressure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Tolvaptan (TLV), a vasopressin type 2 receptor antagonist, is used for heart failure congestion.
- Limited evidence exists regarding its long-term efficacy and optimal use in heart failure management.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs) on tolvaptan in heart failure patients.
- To compare primary and secondary outcomes between tolvaptan and placebo.
Main Methods:
- Systematic review and meta-analysis of double-blinded RCTs.
- Inclusion of studies regardless of language or publication date.
- Primary outcomes: all-cause mortality, body weight, urine volume, serum sodium.
Main Results:
- Tolvaptan demonstrated benefits in reducing body weight and increasing urine volume and serum sodium levels.
- No significant reduction in all-cause mortality was observed.
- Subgroup analysis suggested potential mortality benefits in hyponatremic patients.
- Tolvaptan appeared safe, without worsening renal function or causing hypotension.
Conclusions:
- Meta-analysis indicates short-term benefits of tolvaptan in heart failure patients.
- The impact of tolvaptan on mortality requires further investigation.
- Tolvaptan is a potentially safe option for managing heart failure symptoms.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:22Heart Failure VI: Adjunct Therapies
531
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
531
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:30Heart Failure V: Medical Management
506
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
506
01:30Heart Failure IV: Classification and Diagnostic Evaluation
565
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
565